Investors

Overview

Corporate Profile

Gamida Cell is a clinical-stage biopharmaceutical company committed to developing novel cell therapies with the potential to cure difficult-to-treat cancers and rare, serious hematologic diseases. We are leveraging our proprietary nicotinamide-based cell expansion technology, or NAM technology, to develop product candidates designed to address the limitations of cell therapies.

Copyright West LLC. Minimum 15 minutes delayed.

Latest News

View All
Jun 05, 2019

Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer

Read More
May 31, 2019

Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting

Read More
May 29, 2019

Gamida Cell to Hold Annual Meeting of Stockholders

Read More
May 09, 2019

Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City

Read More
May 07, 2019

Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update

Read More
Apr 30, 2019

Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast

Read More
Apr 22, 2019

Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

Read More
Apr 05, 2019

Gamida Cell to Present at the 18th Annual Needham Healthcare Conference

Read More
Mar 21, 2019

Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors

Read More
Feb 25, 2019

Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

Read More
Feb 23, 2019

Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

Read More
Feb 21, 2019

Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting

Read More
Feb 19, 2019

Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Read More
Feb 14, 2019

Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting

Read More
Jan 24, 2019

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting

Read More
Jan 22, 2019

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

Read More
Jan 07, 2019

Gamida Cell Announces 2019 Goals and Provides Company Update

Read More
Dec 04, 2018

Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology

Read More
Dec 03, 2018

Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting

Read More
Nov 28, 2018

Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Read More
Upcoming Events
More events are coming soon.

Investor & Media Contact

Jaren Irene Madden
Vice President of Investor Relations and Corporate Communications
Gamida Cell Ltd.
IRPR@gamida-cell.com